12-Month Data Presented for MedAllianceâs Selution SLR in BTK Lesions
Created with Sketch.
January 28, 2021 MedAlliance announced that 12-month results from the PRESTIGE below-the-knee (BTK) study were presented as a late-breaking trial at LINC 2021, the Leipzig Interventional Course held as a virtual event January 25-29. The study sought to evaluate the safety and performance of the Selution SLR, the company’s sirolimus-eluting balloon for the treatment of long tibial occlusive lesions (TASC C & D) in patients with critical limb ischemia.
According to the company, PRESTIGE is a prospective, single-center, physician-initiated clinical study conducted by Associate Professor Tze Tec Chong, MD, and Tjun Yip Tang, MD, who are Senior Consultants in the Department of Vascular Surgery at Singapore General Hospital in Singapore.